Fireside Chat – Bill Burkoth – Pfizer VenturesByWhite Hat
Published: 2018-10-18 13:08:37
Bill Burkoth is currently an Executive Director of Pfizer
Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early
2004, Bill has played an instrumental role in numerous new venture capital
investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly),
Clovis Oncology (Nasdaq: CLVS), DVS Sciences
(acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital),
HandyLab (acquired by Becton Dickinson), and HD Biosciences (acquired by Wuxi
AppTec). Bill currently serves on the board of directors of AMRA,
Biodesy, DIR Technologies, G-Con Manufacturing, NeuMoDx Molecular, Novocure
(Nasdaq: NVCR), Palleon Pharma, RefleXion Medical, and Strata Oncology.
He is also a member of the investment committee of the Investment Fund for
Health in Africa (IFHA) and FinHealth Gestão de Recursos S.A. (Rio,
Prior to joining Pfizer, Bill worked in Business Development
at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his
roles in business development, Bill was an analyst at Bay City Capital. Mr.
Burkoth received a BA in chemistry from Whitman College and an MBA from
Columbia Business School.